Sign up to save your podcasts
Or
Share Recognizing the Role of Capmatinib for METex14 in NSCLC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Recognizing the Role of Capmatinib for METex14 in NSCLC
Host: Jacob Sands, MD
Guest: Edward B. Garon, MD, MS
Recently approved capmatinib may be a new treatment for patients with metastatic non-small cell lung cancer who have MET exon 14 skipping mutations. To learn more about this emerging treatment option, Dr. Jacob Sands speaks with Dr. Edward Garon from the David Geffen School of Medicine at the University of California in Los Angeles to explore data from the GEOMETRY Mono-1 study.
View all episodes
By ReachMDHost: Jacob Sands, MD
Guest: Edward B. Garon, MD, MS
Recently approved capmatinib may be a new treatment for patients with metastatic non-small cell lung cancer who have MET exon 14 skipping mutations. To learn more about this emerging treatment option, Dr. Jacob Sands speaks with Dr. Edward Garon from the David Geffen School of Medicine at the University of California in Los Angeles to explore data from the GEOMETRY Mono-1 study.